Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) and Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT – Get Free Report) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, risk, valuation, profitability, analyst recommendations and institutional ownership.
Analyst Recommendations
This is a summary of current ratings and target prices for Ionis Pharmaceuticals and Lakefront Biotherapeutics American Depositary Shares, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Ionis Pharmaceuticals | 1 | 3 | 19 | 0 | 2.78 |
| Lakefront Biotherapeutics American Depositary Shares | 0 | 5 | 2 | 1 | 2.50 |
Ionis Pharmaceuticals presently has a consensus target price of $75.71, indicating a potential upside of 160.54%. Lakefront Biotherapeutics American Depositary Shares has a consensus target price of $35.50, indicating a potential upside of 4.47%. Given Ionis Pharmaceuticals’ stronger consensus rating and higher probable upside, research analysts clearly believe Ionis Pharmaceuticals is more favorable than Lakefront Biotherapeutics American Depositary Shares.
Profitability
This table compares Ionis Pharmaceuticals and Lakefront Biotherapeutics American Depositary Shares’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Ionis Pharmaceuticals | -56.98% | -120.62% | -16.99% |
| Lakefront Biotherapeutics American Depositary Shares | N/A | N/A | N/A |
Volatility and Risk
Ionis Pharmaceuticals has a beta of 0.43, suggesting that its stock price is 57% less volatile than the S&P 500. Comparatively, Lakefront Biotherapeutics American Depositary Shares has a beta of 0.22, suggesting that its stock price is 78% less volatile than the S&P 500.
Earnings and Valuation
This table compares Ionis Pharmaceuticals and Lakefront Biotherapeutics American Depositary Shares”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Ionis Pharmaceuticals | $944.00 million | 5.13 | -$381.39 million | ($3.32) | -8.75 |
| Lakefront Biotherapeutics American Depositary Shares | $926.99 million | 2.42 | $363.05 million | ($1.41) | -24.10 |
Lakefront Biotherapeutics American Depositary Shares has lower revenue, but higher earnings than Ionis Pharmaceuticals. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than Ionis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
93.9% of Ionis Pharmaceuticals shares are held by institutional investors. Comparatively, 32.5% of Lakefront Biotherapeutics American Depositary Shares shares are held by institutional investors. 1.8% of Ionis Pharmaceuticals shares are held by company insiders. Comparatively, 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Summary
Ionis Pharmaceuticals beats Lakefront Biotherapeutics American Depositary Shares on 8 of the 15 factors compared between the two stocks.
About Ionis Pharmaceuticals
Ionis Pharmaceuticals is a biotechnology company that discovers and develops RNA-targeted medicines, with a focus on antisense oligonucleotides. Its medicines are designed to act on RNA and change the production of proteins linked to disease. The company’s research and development programs span neurological, cardiovascular, metabolic and rare diseases. Ionis has developed medicines that it commercializes itself and products advanced or marketed with pharmaceutical partners. Its medicines and partnered products include treatments for conditions such as spinal muscular atrophy and transthyretin amyloidosis.
About Lakefront Biotherapeutics American Depositary Shares
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company’s pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis.
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
